Oxford Biomedica PLC Total Voting Rights (5268N)
February 01 2021 - 3:47AM
UK Regulatory
TIDMOXB
RNS Number : 5268N
Oxford Biomedica PLC
01 February 2021
Oxford Biomedica
Total Voting Rights
Oxford, UK - 01 February 2021: Oxford Biomedica plc ("Oxford
Biomedica" or "the Company") (LSE: OXB), announces that in
accordance with the FCA's Disclosure Guidance and Transparency Rule
5.6.1, the Company's issued share capital as at the close of
business on 29 January 2021 consisted of 82,372,602 ordinary shares
of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares
held in treasury.
Accordingly, the total number of voting rights in Oxford
Biomedica plc at the date of this notice is 82,372,602.
The above figure (82,372,602) may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Oxford Biomedica plc under the FCA's Disclosure
Guidance and Transparency Rules.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam
Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene
Therapy Consortium and Imperial Innovations, through which it has
long-term economic interests in other potential gene and cell
therapy products. Additionally the group has signed a 3 year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 580 people. Further
information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREANAFELKFEEA
(END) Dow Jones Newswires
February 01, 2021 04:47 ET (09:47 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024